Recruiting

Validation of the CIDI 5.0 Against the SCID-5 for Lifetime Mental Disorders

ClinicalTrials.gov IDNCT07604753

PhaseNot Applicable

Enrollment300

SponsorThe University of Hong Kong

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Posttraumatic Stress Disorder (PTSD)

About this study

The World Health Organization Composite International Diagnostic Interview (CIDI) is a fully structured diagnostic tool designed for lay interviewers to assess the prevalence of mental and substance use disorders. Earlier versions, such as the CIDI 3.0, demonstrated acceptable individual-level concordance with clinical assessments based on DSM-IV criteria (Haro et al. 2006). The latest iteration (CIDI 5.0) has been updated to operationalize DSM-5 criteria. Recent evidence from a large-scale, community-based national study in Qatar suggests that under DSM-5 criteria (Khaled et al. 2024), after recalibration, the CIDI 5.0 maintains high specificity (91.9% for MDD, 94.7% for GAD, and 85.5% for PTSD). Sensitivity suggested CIDI diagnoses aligned closely with clinical "gold standard" diagnoses (51.5% for MDD, 50.7% for GAD, and 77.3% for PTSD). Despite the evidence from Qatar, there remains a lack of evidence regarding the validity of the CIDI 5.0 in population-based studies. Therefore, this study aims to evaluate the diagnostic validity of the CIDI 5.0 for Lifetime MDD, GAD, and PTSD, using the Structured Clinical Interview for DSM-5 (SCID-5) as the definitive clinical gold standard.

Interventions

Diagnostic Test: CIDI-5 — The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10). Trained interviewers will administer selected modules from the Hong Kong version of the CIDI-5 in a computer-assisted personal interview to measure the outcomes. To validate the diagnoses in the CIDI-5 group, investigators will conduct clinical re-interviews of 3 selected CIDI-5 diagnoses: major depressive disorder (MDD), generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD) using the Structured Clinician Interview for DSM-5 (SCID) by a trained mental health professional with previous experience using SCID.

Primary outcomes

Depression (Immediately following intervention or recruitment)
Worry and Anxiety (Immediately following intervention or recruitment)
Stressful Experiences (Immediately following intervention or recruitment)

Eligibility information

Inclusion Criteria: * All household members aged 18 years old and over are randomly sampled from the Census and Statistics Department List of Quarters * Live in the address sampled from the Census and Statistics Department List of Quarters * Reside in Hong Kong for at least six months in the past year * Able to read and communicate in Chinese or English * Without linguistic or cognitive difficulties Exclusion Criteria: * Domestic workers

Study locations

The University of Hong Kong, Hong Kong, Hong Kong

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.